Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Alligator, Capricor, CSL, Dyne, Ferrer, Geovax, GSK, Hemogenyx, Tisento.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avata, Escugen, Glykos, Immedica, Intact, Oceanus, Orion, Processa, Sunrock.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acurx, Azitra, Immuneering, Lyell, Mineralys, Spyre, Ventyx.
Avata Biosciences Holdings Ltd. and Oceanus Bio Inc. have inked a drug discovery and development deal worth up to $95 million for two of Avata’s cannabidiol compounds.
After years of conversations surrounding indirect research costs, academic groups are now under the gun to quickly come up with an alternative to the NIH’s proposed 15% across-the-board cap on indirect costs and the decades-old university-by-university negotiated rate that can exceed a 50% add-on to a grant.
Immuneering Corp.’s phase IIa data from an ongoing trial in pancreatic cancer disclosed June 17 impressed Wall Street and brought renewed attention to the perennially difficult indication, at which drug developers continue to fling themselves with varied mechanisms.
RSS
